CSIMarket
 
Enveric Biosciences Inc   (ENVB)
Other Ticker:  
 
 
Price: $0.8514 $-0.13 -13.122%
Day's High: $0.9501 Week Perf: -1.67 %
Day's Low: $ 0.84 30 Day Perf: -3.52 %
Volume (M): 486 52 Wk High: $ 6.98
Volume (M$): $ 414 52 Wk Avg: $2.05
Open: $0.91 52 Wk Low: $0.65



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 2
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -23
 Cash Flow (TTM) (Millions $) -13
 Capital Exp. (TTM) (Millions $) 1

Enveric Biosciences Inc
Enveric Biosciences Inc. is a biotechnology company that focuses on developing and commercializing innovative therapies for patients suffering from cancer and other serious medical conditions. The company specializes in the research and development of cannabinoid-based pharmaceuticals, utilizing the therapeutic potential of cannabinoids to treat various symptoms and side effects of cancer treatments. Enveric Biosciences' goal is to improve the quality of life for patients by providing effective and safe treatments that address both physical and mental health aspects. The company is committed to conducting rigorous clinical trials and collaborating with healthcare professionals to bring their products to market.


   Company Address: 4851 Tamiami Trail N Naples 34103 FL
   Company Phone Number: 302-1707   Stock Exchange / Ticker: NASDAQ ENVB
   ENVB is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Business Update

Advancements in Cancer-Targeting Cannabinoid-Related Intellectual Property: Enveric Biosciences' Innovative Approach

Published Fri, Feb 23 2024 1:00 PM UTC

Enveric Biosciences, a forward-thinking biotechnology company, has made significant strides in the field of cancer treatment through the development of novel neuroplastogenic small-molecule therapeutics. As part of their ongoing commitment to revolutionizing the treatment landscape, Enveric recently announced the sale of one of their cancer-related patent portfolios. This de...

Product Service News

Enveric Biosciences Discovers Promising Novel Compounds for Mental Health Disorders, Advancing Neuroplastogenic Therapeutics

Published Wed, Feb 21 2024 1:00 PM UTC

Enveric Biosciences Unveils Novel Compounds for Mental Health Disorders: A Step Towards Breakthrough Neuroplastogenic Therapeutics Enveric Biosciences, a prominent biotechnology company, has recently unveiled a library of preclinical compounds targeting mental health disorders. The company's advanced Psybrary platform and proprietary computational chemistry and artificial in...

Product Service News

Enveric Biosciences Unveils Groundbreaking Lead Drug Candidate Shaping the Future of Mental Health Treatment

Published Wed, Jan 3 2024 1:00 PM UTC

Enveric Biosciences, a pioneering biotechnology company specializing in the development of novel neuroplastogenic small-molecule therapeutics for mental health disorders, has recently provided an update on the selection of EB-003 as its lead drug candidate from their advanced EVM301 Series. This update is a significant step forward for the company's mission to address the pr...

Stock Transactions

Enveric Biosciences Raises $1.8 Million Through Warrant Exercise and Private Placement, Bolstering Efforts to Revolutionize Mental Health Treatment

Published Fri, Dec 29 2023 1:52 PM UTC

Enveric Biosciences Announces Successful Exercise of Warrants and New Issuance in Private Placement for $1.8 Million Gross Proceeds
CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB), a biotechnology company specializing in the development of innovative neuroplastogenic small-molecule therapeutics for depression, anxiety, and addiction disorders, announced today the e...

Product Service News

Enveric Biosciences Selects EB-003 as Promising Lead Drug Candidate for Neuroplastogenic Treatment Therapies

Published Thu, Dec 28 2023 1:00 PM UTC

Cambridge, Mass. - Enveric Biosciences (NASDAQ: ENVB), a renowned biotechnology company focused on developing innovative small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, has announced the selection of EB-003 as its lead drug candidate from the EVM301 Series. With groundbreaking potential, EB-003 has the capability to revolutioniz...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com